LEXICON PHARMACEUTICALS INC (LXRX)
Health Care · Cardiovascular, metabolic, and neuropathic disease therapeutics · NASDAQ
An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by commercialized INPEFA and Phase 3 hypertrophic cardiomyopathy candidate sotagliflozin.
What LEXICON PHARMACEUTICALS INC does
Lexicon Pharmaceuticals is a biopharmaceutical company developing small-molecule drug candidates and commercializing INPEFA (sotagliflozin) for cardiovascular and metabolic indications. The company is advancing sotagliflozin in hypertrophic cardiomyopathy and type 1 diabetes, pilavapadin in neuropathic pain, and has licensed LX9851 to Novo Nordisk for obesity and cardiometabolic disorders, while pursuing preclinical programs based on target-driven drug discovery from systematic gene knockout studies.
Themes: ["Cardiovascular disease / heart failure","Type 1 and type 2 diabetes","Obesity and GLP-1 adjacent cardiometabolic disorders","Neuropathic pain / diabetic peripheral neuropathy","Chronic kidney disease","Gene-based target discovery"]
Fundamentals
- Price$2.25 as of 2026-07-09 close
- Market cap$1.0B as of 2026-07-10
- 1-year return+110.3% as of 2026-07-09 close
- Net margin-37.5% as of 2026-07-10
- Gross margin+99.5% as of 2026-07-10
- ROE-18.6% as of 2026-07-10
- Debt / equity0.24 as of 2026-07-10
- Revenue growth (YoY)+123.1% as of 2026-07-10
- Revenue CAGR (3y)+610.3% SEC XBRL
- Beta1.03 as of 2026-07-10
Key risks (from latest filing)
["Regulatory risk: ZYNQUISTA NDA for type 1 diabetes has received two complete response letters and is under FDA Notice of Opportunity for Hearing proceedings; approval uncertain pending third-party safety study","Commercial traction risk: Net product revenue of $1.1M in Q1 2026 indicates early-stage INPEFA commercialization; profitability and market adoption uncertain","Partnership dependency: LX9851 obesity program entirely dependent on Novo Nordisk development and commercialization; pilavapadin advancement relies on third-party collaboration discussions"]
Competitors & peers
- Novo Nordisk (NVO) - obesity and diabetes
- AstraZeneca (AZN) - heart failure and cardiovascular
- Boehringer Ingelheim - SGLT inhibitors and heart failure
- Bayer (BAYN) - cardiovascular and kidney disease
- Eli Lilly (LLY) - diabetes and obesity
- Pfizer (PFE) - cardiovascular and diabetes
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.